No posts published in this language yet
Once posts are published, you’ll see them here.
top of page
Our Vision
It is our mission to innovate the clinical trials world through disrupting outdated processes and organizational structures.
(Sven Engel, CEO of SynapCon)
Our innovative solutions optimize the interface between patient data, clinics and the industry that develops drugs and medical devices. This includes the implementation of our digital solutions and coordinated consulting to optimize proscesses.
We optimize the interfaces between patient data, clinics and the industry.
The digital solutions and individual consulting we provide help enhance your processes. The vast amount of clinical data provides us with profund market knowledge of the entire medical value chain. We not only help you to shorten your development cycles to ensure faster patient care, but also to reduce development costs to make innovative medicines affordable.
Our Story
Founded after the Brexit in May 2021 from a predeceasing Ltd., the new SynapCon GmbH keeps improving its advanced technologies and business models with a clear focus on accelerating the clinical development of drugs and medical devices, making products available to patients more quickly and reducing the burden on healthcare systems in the long term.
Thanks to a notice to sponsors from the EMA our product has never seen a better time to show off its capabilities.
In 2005 our CEO Sven Engel was a managing director of the CRO he founded. During that time, he held a responsible position at the Jerini Ag and contributed in the clinical development of a drug against the rare disease of hereditary angioedema.
After the takeover of Jerini by Shire Ltd., he was responsible for the further projects up to FDA approval. The CTM system EasyClin(c) which he had developed, was used in two global studies and thanks to this new, oustanding system, he was able to keep the calculated time and cost framework at 100%.
The system then got validated in 2010 according to 21 CFR part 11. Moreover, it got approved by the client and accepted by the FDA.
Studies usually lead to long delays and high costs due to manual post-proccessing. This can now be avoided with the use of our systems. At peak times, up to 250 users worldwide (doctors, laboratories, CRAs, etc:) at the same time use one single installation.
Experienced Leadership
Key Aspects
It is our mission to innovate the clinical trials world through disrupting outdated processes and organizational structures.
Our innovative solutions optimize the interface between patient data, clinics and the industry that develops drugs and medical devices. This includes the implementation of our digital solutions and coordinated consulting to optimize processes.
bottom of page